Shares of CeriBell (NASDAQ:CBLL – Get Free Report) have received a consensus recommendation of “Buy” from the six ratings firms that are covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have issued a report on the stock in the last year is $32.60.
CBLL has been the topic of a number of recent research reports. William Blair began coverage on CeriBell in a research note on Tuesday, November 5th. They set an “outperform” rating on the stock. TD Cowen increased their price objective on CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Bank of America assumed coverage on shares of CeriBell in a report on Tuesday, November 5th. They set a “buy” rating and a $32.00 price target for the company. Canaccord Genuity Group initiated coverage on shares of CeriBell in a research report on Tuesday, November 5th. They issued a “buy” rating and a $30.00 price objective on the stock. Finally, JPMorgan Chase & Co. began coverage on CeriBell in a research note on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 target price on the stock.
Get Our Latest Research Report on CBLL
CeriBell Price Performance
CeriBell (NASDAQ:CBLL – Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The company had revenue of $17.20 million during the quarter, compared to analyst estimates of $17.06 million. On average, equities research analysts anticipate that CeriBell will post -2.46 EPS for the current fiscal year.
CeriBell Company Profile
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
See Also
- Five stocks we like better than CeriBell
- Energy and Oil Stocks Explained
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- 3 Healthcare Dividend Stocks to Buy
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- What is a Low P/E Ratio and What Does it Tell Investors?
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.